• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒2型木瓜样蛋白酶(PL)的基于片段的筛选

Fragment-Based Screen of SARS-CoV-2 Papain-like Protease (PL).

作者信息

Taylor Ashley J, Amporndanai Kangsa, Rietz Tyson A, Zhao Bin, Thiruvaipati Anusha, Wei Qiangqiang, South Taylor M, Crow Mackenzie M, Apakama Chideraa, Sensintaffar John L, Phan Jason, Lee Taekyu, Fesik Stephen W

机构信息

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, United States.

Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6600, United States.

出版信息

ACS Med Chem Lett. 2024 Jul 23;15(8):1351-1357. doi: 10.1021/acsmedchemlett.4c00238. eCollection 2024 Aug 8.

DOI:10.1021/acsmedchemlett.4c00238
PMID:39140055
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11318101/
Abstract

Coronaviruses have been responsible for numerous viral outbreaks in the past two decades due to the high transmission rate of this family of viruses. The deadliest outbreak is the recent Covid-19 pandemic, which resulted in over 7 million deaths worldwide. SARS-CoV-2 papain-like protease (PL) plays a key role in both viral replication and host immune suppression and is highly conserved across the coronavirus family, making it an ideal drug target. Herein we describe a fragment-based screen against PL using protein-observed NMR experiments, identifying 77 hit fragments. Analyses of NMR perturbation patterns and X-ray cocrystallized structures reveal fragments bind to two distinct regions of the protein. Importantly none of the fragments identified belong to the same chemical class as the few reported inhibitors, allowing for the discovery of a novel class of PL inhibitors.

摘要

在过去二十年中,冠状病毒因其高传播率导致了众多病毒爆发。最致命的疫情是最近的新冠疫情,在全球造成了超过700万人死亡。严重急性呼吸综合征冠状病毒2型木瓜样蛋白酶(PL)在病毒复制和宿主免疫抑制中都起着关键作用,并且在冠状病毒家族中高度保守,使其成为理想的药物靶点。在此,我们描述了一项使用蛋白质观测核磁共振实验针对PL的基于片段的筛选,鉴定出77个命中片段。对核磁共振扰动模式和X射线共结晶结构的分析表明,这些片段与该蛋白质的两个不同区域结合。重要的是,所鉴定的片段均不属于少数已报道抑制剂的同一化学类别,从而有可能发现一类新型的PL抑制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9794/11318101/8e3686b3efcf/ml4c00238_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9794/11318101/5c59fffd1414/ml4c00238_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9794/11318101/e54467034200/ml4c00238_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9794/11318101/303e7e0c1e1f/ml4c00238_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9794/11318101/176da9975237/ml4c00238_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9794/11318101/8e3686b3efcf/ml4c00238_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9794/11318101/5c59fffd1414/ml4c00238_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9794/11318101/e54467034200/ml4c00238_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9794/11318101/303e7e0c1e1f/ml4c00238_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9794/11318101/176da9975237/ml4c00238_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9794/11318101/8e3686b3efcf/ml4c00238_0005.jpg

相似文献

1
Fragment-Based Screen of SARS-CoV-2 Papain-like Protease (PL).严重急性呼吸综合征冠状病毒2型木瓜样蛋白酶(PL)的基于片段的筛选
ACS Med Chem Lett. 2024 Jul 23;15(8):1351-1357. doi: 10.1021/acsmedchemlett.4c00238. eCollection 2024 Aug 8.
2
Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.建立基于模拟的计算管道,以寻找针对 SARS-CoV-2 木瓜蛋白酶样蛋白酶的新型抑制性支架。
Molecules. 2021 Feb 20;26(4):1134. doi: 10.3390/molecules26041134.
3
Structure-based design of SARS-CoV-2 papain-like protease inhibitors.基于结构的 SARS-CoV-2 木瓜蛋白酶样蛋白酶抑制剂设计。
Eur J Med Chem. 2024 Jan 15;264:116011. doi: 10.1016/j.ejmech.2023.116011. Epub 2023 Dec 5.
4
Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M and Papain-like Protease PL of SARS-CoV-2.基于结构的新型 SARS-CoV-2 主要蛋白酶 M 和木瓜蛋白酶样蛋白酶 PL 抑制剂萘醌及其衍生物的鉴定。
J Chem Inf Model. 2022 Dec 26;62(24):6553-6573. doi: 10.1021/acs.jcim.2c00693. Epub 2022 Aug 12.
5
Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches.利用计算方法发现人类冠状病毒泛木瓜蛋白酶样蛋白酶抑制剂
J Pharm Anal. 2020 Dec;10(6):546-559. doi: 10.1016/j.jpha.2020.08.012. Epub 2020 Aug 28.
6
Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor.二 Eckol 和 1,2,3,4,6 - 五没食子酰葡萄糖(PGG)作为新型冠状病毒 2 型主要蛋白酶抑制剂的失效以及 PGG 作为木瓜蛋白酶样蛋白酶抑制剂的发现。
Med Chem Res. 2022;31(7):1147-1153. doi: 10.1007/s00044-022-02903-0. Epub 2022 May 12.
7
Current Strategies of Antiviral Drug Discovery for COVID-19.新型冠状病毒肺炎抗病毒药物研发的当前策略
Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021.
8
Compounds derived from Humulus lupulus inhibit SARS-CoV-2 papain-like protease and virus replication.葎草属化合物抑制 SARS-CoV-2 木瓜样蛋白酶和病毒复制。
Phytomedicine. 2024 Jan;123:155176. doi: 10.1016/j.phymed.2023.155176. Epub 2023 Oct 30.
9
Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor.二 Eckol 和 1,2,3,4,6 - 五没食子酰葡萄糖(PGG)作为新型冠状病毒 2 型主要蛋白酶抑制剂的失效以及 PGG 作为木瓜蛋白酶样蛋白酶抑制剂的发现。
Res Sq. 2022 Mar 30:rs.3.rs-1490282. doi: 10.21203/rs.3.rs-1490282/v1.
10
Molecular docking and simulation studies of natural compounds of L. against papain-like protease (PL) of SARS CoV-2 (coronavirus) to conquer the pandemic situation in the world.基于分子对接和模拟研究,探讨了 L. 的天然化合物对 SARS CoV-2(冠状病毒)木瓜蛋白酶样蛋白酶(PL)的抑制作用,以期攻克当前世界范围内的大流行病局势。
J Biomol Struct Dyn. 2022 Aug;40(12):5665-5686. doi: 10.1080/07391102.2021.1873185. Epub 2021 Jan 18.

引用本文的文献

1
Identification of naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like protease.新型冠状病毒木瓜样蛋白酶天然存在的耐药性突变的鉴定
Nat Commun. 2025 May 16;16(1):4548. doi: 10.1038/s41467-025-59922-9.
2
Analysis of Structures of SARS-CoV-2 Papain-like Protease Bound with Ligands Unveils Structural Features for Inhibiting the Enzyme.与配体结合的严重急性呼吸综合征冠状病毒2木瓜样蛋白酶结构分析揭示了抑制该酶的结构特征。
Molecules. 2025 Jan 23;30(3):491. doi: 10.3390/molecules30030491.

本文引用的文献

1
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model.设计一种具有抗 SARS-CoV-2 木瓜蛋白酶样蛋白酶活性的抑制剂,在小鼠模型中具有抗病毒疗效。
Science. 2024 Mar 29;383(6690):1434-1440. doi: 10.1126/science.adm9724. Epub 2024 Mar 28.
2
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.SARS-CoV-2 对奈玛特韦耐药的分子机制。
Nature. 2023 Oct;622(7982):376-382. doi: 10.1038/s41586-023-06609-0. Epub 2023 Sep 11.
3
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir.
严重急性呼吸综合征冠状病毒2型主要蛋白酶的自然发生突变赋予对奈玛特韦的耐药性。
ACS Cent Sci. 2023 Jul 24;9(8):1658-1669. doi: 10.1021/acscentsci.3c00538. eCollection 2023 Aug 23.
4
NMR Characterization of the Papain-like Protease from SARS-CoV-2 Identifies the Conformational Heterogeneity in Its Inhibitor-Binding Site.NMR characterization of the papain-like protease from SARS-CoV-2 identifies the conformational heterogeneity in its inhibitor-binding site.
J Am Chem Soc. 2023 Aug 2;145(30):16669-16677. doi: 10.1021/jacs.3c04115. Epub 2023 Jul 21.
5
Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin.双结构域识别决定了 SARS-CoV-2 PLpro 对人 ISG15 和 K48 连接的二泛素的选择性。
Nat Commun. 2023 Apr 25;14(1):2366. doi: 10.1038/s41467-023-38031-5.
6
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2.强效且选择性抑制 SARS-CoV-2 的木瓜蛋白酶样蛋白酶。
Nat Commun. 2023 Mar 28;14(1):1733. doi: 10.1038/s41467-023-37254-w.
7
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.SARS-CoV-2 对奈玛特韦产生耐药性的多种途径。
Nature. 2023 Jan;613(7944):558-564. doi: 10.1038/s41586-022-05514-2. Epub 2022 Nov 9.
8
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.靶向 SARS-CoV-2 木瓜蛋白酶样蛋白酶的进展与挑战。
J Med Chem. 2022 Jun 9;65(11):7561-7580. doi: 10.1021/acs.jmedchem.2c00303. Epub 2022 May 27.
9
An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.一种用于治疗 COVID-19 的口服 SARS-CoV-2 M 抑制剂临床候选药物。
Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.
10
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.利用结合协同性设计针对 COVID-19 抗病毒治疗的 SARS-CoV-2 PLpro 抑制剂。
J Med Chem. 2022 Feb 24;65(4):2940-2955. doi: 10.1021/acs.jmedchem.1c01307. Epub 2021 Oct 19.